LENZ Therapeutics Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 LENZ Therapeutics Inc 公司

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

LENZ Therapeutics Inc简介



公司代码LENZ

公司名称LENZ Therapeutics Inc

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

员工数量42

证券类型Ordinary Share

年结日Jun 25

公司地址- -

城市- -

上市交易所NASDAQ OMX - NASDAQ BASIC

国家- -

邮编- -

电话- -

网址- -

公司代码LENZ

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

LENZ Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. James Mccollum

Independent Director

631.10K

--

Mr. Marc Odrich

Chief Medical Officer

100.20K

+0.60%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

12.89K

+58.20%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

Dr. Frederic (Fred) Guerard, Pharm.D.

Independent Director

--

Jeff W. George

Independent Chairman of the Board

--

Ms. Shelley B. Thunen

Independent Director

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. James Mccollum

Independent Director

631.10K

--

Mr. Marc Odrich

Chief Medical Officer

100.20K

+0.60%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

12.89K

+58.20%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 5月13日周三

持股股东

股东类型

持股股东

占比

RA Capital Management, LP

13.33%

Fidelity Management & Research Company LLC

11.81%

Alpha Wave Global, LP

11.52%

Versant Ventures

8.47%

Squarepoint Capital LLP

5.08%

其他

49.79%

持股股东

占比

RA Capital Management, LP

13.33%

Fidelity Management & Research Company LLC

11.81%

Alpha Wave Global, LP

11.52%

Versant Ventures

8.47%

Squarepoint Capital LLP

5.08%

其他

49.79%

股东类型

持股股东

占比

Investment Advisor

42.54%

Venture Capital

33.60%

Investment Advisor/Hedge Fund

21.57%

Hedge Fund

14.43%

Individual Investor

2.65%

Research Firm

2.10%

Pension Fund

0.54%

Bank and Trust

0.16%

Private Equity

0.16%

机构持股



更新时间: 4月1日周三

报告期

机构数

持股数

持股占比

持股变动

2026Q1

347

36.30M

115.82%

+853.08K

2025Q4

309

33.95M

108.49%

+1.00M

2025Q3

267

30.95M

100.67%

+981.38K

2025Q2

245

29.52M

104.44%

-639.13K

2025Q1

245

28.95M

104.22%

-285.84K

2024Q4

225

27.65M

100.55%

-350.42K

2024Q3

204

26.43M

96.17%

-1.73M

2024Q2

197

25.06M

103.06%

+4.18M

2024Q1

204

22.41M

93.92%

+12.70M

2023Q4

200

7.73M

92.24%

-2.14M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

RA Capital Management, LP

4.18M

13.33%

--

Dec 31, 2025

Fidelity Management & Research Company LLC

3.70M

11.81%

+3.62M

+4140.74%

Dec 31, 2025

Alpha Wave Global, LP

3.61M

11.52%

--

Dec 31, 2025

Versant Ventures

2.66M

8.47%

--

Dec 31, 2025

Squarepoint Capital LLP

491.90K

1.57%

+402.11K

+447.84%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

1.47M

4.68%

+146.33K

+11.08%

Dec 31, 2025

abrdn Inc.

489.43K

1.56%

+358.71K

+274.40%

Dec 31, 2025

Franklin Advisers, Inc.

1.09M

3.48%

+540.65K

+98.41%

Dec 31, 2025

72 Investment Holdings, LLC

1.02M

3.25%

--

Dec 31, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.04%

Virtus LifeSci Biotech Clinical Trials ETF

0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

0.27%

iShares U.S. Pharmaceuticals ETF

0.22%

ProShares Ultra Nasdaq Biotechnology

0.11%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.08%

iShares Biotechnology ETF

0.06%

State Street SPDR S&P Pharmaceuticals ETF

占比1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.04%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

占比0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.27%

iShares U.S. Pharmaceuticals ETF

占比0.22%

ProShares Ultra Nasdaq Biotechnology

占比0.11%

iShares Micro-Cap ETF

占比0.09%

Invesco Nasdaq Biotechnology ETF

占比0.08%

iShares Biotechnology ETF

占比0.06%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

公告日期

除权除息日

类型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1